THE CHOICE OF THE ANTIHYPERTENSIVE DRUG IN SPECIAL CONDITIONS: EVIDENCE-BASED DATA IN CO-MORBID HYPERTENSION AND METABOLIC DISORDERS (part 3)
https://doi.org/10.18705/1607-419X-2014-20-5-
Abstract
The article reviews the main approaches to the hypertension management in metabolic disorders, including diabetes, dyslipidemia, hyperuricemia and gout, as well as in sleep apnea. The data are based on the guidelines by the Joint National Committee of theUSA, European Society of Cardiology/European Society of Hypertension, American Society of Hypertension/International Society of Hypertension, considering the important issues mentioned in national guidelines by Russian Society of Cardiology.
About the Authors
I. S. Korostovtseva
Federal Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
Corresponding author: Federal Almazov Medical Research Centre, 2 Akkuratov st.,St Petersburg,Russia, 197341. Tel./fax: +7(812)702–55–95. MD, PhD, Senior Researcher at the Laboratory of Diabetology in theInstituteofEndocrinologyat the Federal Almazov Medical Research Centre
N. E. Zvartau
Federal Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
Corresponding author: Federal Almazov Medical Research Centre, 2 Akkuratov st., St Petersburg, Russia, 197341. Phone: +7(812)702–68–10
Yu. V. Sviryaev
Federal Almazov Medical Research Centre, St Petersburg.
Institute of Experimental Physiology and Biochemistry n.a. I.M. Sechenov of Russian Academy
of Sciences, St Petersburg
Russian Federation
Russian Federation
A. O. Konradi
Federal Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
References
1. James P.A., Oparil S., Carter B.L. et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) // J. Am. Med. Assoc. — 2014. Vol. 311, № 5. — Р. 507–520.
2. Weber M.A., Schiffrin E.L., White W.B. et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the International society of hypertension // J. Hypertens. — 2014. — Vol. 32, № 1. — Р. 3–15.
3. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. — 2013. — Vol. 31, № 7. — Р. 281–357.
4. Национальные рекомендации по кардиоваскулярной профилактике // Кардиоваскулярная терапия и профилактика. — 2011. — Т. 10, № 6, прил. — 64 с. / National guidelines on cardiovascular prevention // Cardiovascular Therapy and Prevention [Kardovskuliarnaia Terapiia i Profilaktika]. — 2011. — Vol. 10, № 6, suppl. — 64 p. [Russian].
5. Баранова Е.И. Лечение артериальной гипертензии в особых группах пациентов (рекомендации по лечению артериальной гипертензии 2013 года Европейского общества по артериальной гипертензии и Европейского общества кардиологов) // Артериальная гипертензия. — 2014. — Т. 20, № 1. — С. 38–44. / Baranova E.I. Treatment strategies of arterial hypertension in special conditions (2013 European Society of Hypertension and European Society of Cardiology guidelines for the management of arterial hypertension) // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2014. — Vol. 20, № 1. — P. 38–44 [Russian].
6. Коростовцева Л.С., Звартау Н.Э., Конради А.О. Выбор антигипертензивного препарата в особых группах пациентов: данные доказательной медицины при сочетанной сердечно-сосудистой патологии (часть 1) // Артериальная гипертензия. — 2014. — Т. 20, № 3. — С. 147–151. / Korostovtseva L.S., Zvartau N.E., Konradi A.O. The choice of the antihypertensive drug in special conditions: evidence-based data in co-morbid cardiovascular diseases // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2014. — Vol. 20, № 3. — P. 147–151 [Russian].
7. Авдонина Н.Г., Коростовцева Л.С., Иртюга О.Б., Звартау Н.Э., Конради А.О. Выбор антигипертензивного препарата в особых группах пациентов: возрастные и гендерные различия (часть 2) // Артериальная гипертензия. — 2014. — Т. 20, № 4. — С. 232–237. / Avdonina N.G., Korostovtseva L.S., Irtyuga O.B., Zvartau N.E., Konradi A.O. The choice of the antihypertensive drug in special conditions: gender- and age-related differences // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2014. — Vol. 20, № 4. — P. 232–237 [Russian].
8. Chrisp P., Faulds D. Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension // Drugs. — 1992. — Vol. 44. — P. 993–1012.
9. Haenni A., Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives // J. Hypertens. — 1999. — Vol. 17, Suppl. 3. — P. 29–35.
10. Kaan E.C., Bruckner R. et al. Effects of agmantine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders // Cardiovasc. Risc Factors. — 1995. — Vol. 5, Suppl. 1. — P. 19–27.
11. Chobanian A.V., Bakris G.L., Black H.R. et al. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure // Hypertension. — 2003. — Vol. 42. — P. 1206–1252.
12. Parving H.H., Brenner B.M., McMurray J.J.V., de Zeeuw D., Haffer S.M., Solomon S.D. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes // N. Engl. J. Med. — 2012. — Vol. 367. — P. 2204–2213.
13. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. Jr, Bigger J.T., Buse J.B. et al. Effects of intensive glucose lowering in type 2 diabetes. Action to control cardiovascular risk in diabetes study group // N. Engl. J.Med. — 2008. — Vol. 358, № 24. — Р. 2545–2559.
14. Eeg-Olofsson K., Cederholm J., Nilsson P.M., Zethelius B., Svensson A.M., Gudbjörnsdóttir S. et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR) // Diabetes Care. — 2010. — Vol. 33, № 7. — Р. 1640– 1646.
15. Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study // Arch. Intern. Med. — 2005. — Vol. 165, № 7. — Р. 742–748.
16. Choi H.K., Soriano L.C., Zhang Y., García Rodríguez L.A. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study // Br. Med. J. — 2012. — Vol. 344. — P. d8190.
17. Hamburger M., Baraf H.S., Adamson T.C. 3rd, Basile J., Bass L., Cole B. et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia // Phys. Sportsmed. — 2011. — Vol. 39, № 4. — Р. 98–123.
18. Ghosh M., Majumdar S.R. Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis // Endocrine. — 2014. — Vol. 46, № 3. — Р. 397–405.
19. Kanis J.A., McCloskey E.V., Johansson H., Cooper C., Rizzoli R., Reginster J.Y.; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women // Osteoporos. Int. — 2013. — Vol. 24, № 1. — Р. 23–57.
20. Ilić K., Obradović N., Vujasinović-Stupar N. The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review // Calcif. Tissue Int. — 2013. — Vol. 92, № 3. — Р. 217–227.
21. Hajjar I., Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000 // J. Am. Med. Assoc. — 2003. — Vol. 290, № 2. — P. 199–206.
22. Egan B.M., Basile J.N., Rehman S.U. et al. Plasma renin test- guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial // Am. J. Hypertens. — 2009. — Vol. 22, № 7. — P. 792–801.
23. Котовская Ю.В., Кравцова О.А., Павлова Е.А. Определение активности ренина плазмы как стратегия выбора и изменения антигипертензивной терапии // Артериальная гипертензия. — 2013. — Т. 19, № 5. — С. 380–388. / Kotovskaya Y.V., Kravtsova O.A., Pavlova E.A. Plasma renin assessment as the strategy of hypertension management // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2013. — Vol. 19, № 5. — P. 380–388 [Russian].
24. Parati G., Lombardi C., Hedner J., Bonsignore M.R., Grote L., Tkacova R. et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (Co-operation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea // J. Hypertens. — 2012. — Vol. 30. — P. 633–646.
25. Parati G., Lombardi C., Hedner J., Bonsignore M.R., Grote L. et al. Recommendations for the management of patients with obstructive sleep apnoea and hypertension // Eur. Respir. J. — 2013. — Vol. 41. — P. 523–538.
26. Свиряев Ю.В., Киталаева К.Т., Коростовцева Л.С. и др. Лечение артериальной гипертензией с синдромом обструктивного апноэ во сне — рилменидин против бисопролола // Артериальная гипертензия. — 2007. — Т. 13, № 4. — С. 280–286. / Sviryaev Yu.V., Kitalaeva K.T., Korostovtseva L.S. Treatment of hypertension associated with obstructive sleep apnea syndrome: rihnenidine vs. bisoprolol // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2007. — Vol. 13, № 4. — Р. 280– 286 [Russian].
Review
For citations:
Korostovtseva I.S., Zvartau N.E., Sviryaev Yu.V., Konradi A.O. THE CHOICE OF THE ANTIHYPERTENSIVE DRUG IN SPECIAL CONDITIONS: EVIDENCE-BASED DATA IN CO-MORBID HYPERTENSION AND METABOLIC DISORDERS (part 3). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2014;20(5):370-376. https://doi.org/10.18705/1607-419X-2014-20-5-
Views:
2275
Email this article 